Pulmonary Arterial Hypertension in Eastern Europe

Pharm-Olam was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety of a compound for pulmonary arterial hypertension patients.  This study originally required 670 patients across the globe, but the enrollment was later increased to 1,150 due to study design changes.  Pharm-Olam played an integral part in the enrollment of the additional patients, providing 45% more patients than originally tasked. 

Study Overview:

Pharm-Olam was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety of a compound for pulmonary arterial hypertension patients. This study originally required 670 patients across the globe, but the enrollment was later increased to 1,150 due to study design changes. Pharm-Olam played an integral part in the enrollment of the additional patients, providing 45% more patients than originally tasked.

Click on the image to download the full case study

Pulmonary Arterial Hypertension in Eastern Europe